On May 6, 2025, Haemonetics Corp announced a new market initiative expected to cost approximately $20 million, aiming for annual savings of about $30 million post-completion, with charges incurred through fiscal 2027. Additionally, they issued financial results for the fourth quarter and fiscal year ending March 29, 2025.